Regeneron Pharmaceuticals (REGN) closed at $790.74 on Oct 16, 2026, down 0.7% on the day. The stock is up 0.2% over the past month, up 17.6% over three months, up 2.6% year to date and up 37.5% over the past year. It trades 8.0% below its 52-week high of $859.34 and 38.4% above its 52-week low of $571.35. The close sits below its 50-day moving average ($790.85) and above its 200-day moving average ($735.26).
NextPick tracks REGN in its Biotech basket alongside VRTX, MRNA, BIIB, ALNY and BNTX. As of Oct 16, 2026, the basket's money-flow score is -8 (neutral), and the basket is down 3.4% over five sessions. Over the past month REGN ranks 5th of 17 basket members by price change.
REGN is scheduled to report earnings on Oct 30, 2026.
Regeneron Pharmaceuticals is scheduled to report on Oct 30, 2026.
Yes — the Oct 16, 2026 close of $790.74 is 7.5% above the 200-day average of $735.26.
REGN closed 8.0% below its 52-week high of $859.34.
NextPick groups REGN with VRTX, MRNA, BIIB, ALNY and BNTX in its Biotech basket.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
